Chat with us, powered by LiveChat Thailand Medical News - Home
Source: Eli Lilly and Company  Jan 20, 2019
REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis   Pooled data analyses of AFP-High patients in the REACH-2 and REACH trials showed an improvement of 3.1 months in median overall survival   Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ram...
Source: Washington University School of Medicine , St. Louis   Jan 18, 2019
Scientists working to develop more effective treatments for diabetes are turning to stem cells. Such cells can be transformed into cells that produce insulin, the hormone that controls blood sugar. Researchers at Washington University School of Medicine in St. Louis have tweaked the recipe for coaxing human stem cells into insulin-secreting beta cells and shown that the resulting cells are more ...
Thailand Medical News  Jan 19, 2019
The US FDA  and EU has approved a new sublingual formulation of sufentanil, Dsuvia, for the management of acute pain in adults in medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments. The drug is supplied in a 30 microgram tablet in a single-dose, prefilled applicator for administration by a healthcare professional, and it will not be availa...
Source: NYU Langone Health / NYU School of Medicine  Jan 17, 2019
A new class of engineered proteins may counter infection caused by Staphylococcus aureus -- a bacterial species considered one of the largest global health threats, a new study suggests. Published online Jan. 16 in Science Translational Medicine, the study is the result of a five-year research partnership between scientists at NYU School of Medicine and Janssen Research & Dev...
Presented by
World Leprosy Week 2019 (Sunday 27th January - Saturday 2nd February 2019)
Source: Flinders University  Jan 21, 2019
A new antibiotic developed by a Flinders University researcher is being heralded as a breakthrough in the war against a drug resistant superbug. Bacteria are winning the fight against antibiotics as they evolve to fight off traditional treatments, threatening decades of advancements in modern medicine, with predictions they will kill over 10 million people by 2050. The scientific development o...
Source: Netherlands Institute for Neuroscience - KNAW  Jan 20, 2019
Researchers from the Netherlands Institute for Neuroscience (NIN) and the Leiden University Medical Center (LUMC) have shown that treatment using gene therapy leads to a faster recovery after nerve damage. By combining a surgical repair procedure with gene therapy, the survival of nerve cells and regeneration of nerve fibers over a long distance was stimulated for the first time. The discovery, pu...
Thailand Medical News  Jan 20, 2019
Positive news for Thailand’s healthcare sector was highly welcome when Bloomberg released their Global Health Care Efficiency Index in the last quarter of 2018. Thailand Medical News reviews these extremely positive results and suggest  why momentum must be maintained as well as 2 challenges that must be addressed in order for this momentum to be carried forward on a continuous basis...
Source: University of Michigan  Jan 20, 2019
A new study finds acupressure could be a low-cost, at-home solution to a suite of persistent side effects that linger after breast cancer treatment ends. Researchers from the University of Michigan Rogel Cancer Center reported in 2016 that acupressure helped reduce fatigue in breast cancer survivors. In the new study, they looked at the impact of acupressure on symptoms that frequently accompa...
Source: Eli Lilly and Company  Jan 20, 2019
REACH-2 is the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population known for poor prognosis   Pooled data analyses of AFP-High patients in the REACH-2 and REACH trials showed an improvement of 3.1 months in median overall survival   Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ram...